Francesco Nai

Francesco Nai

Auto-generated profile, based on publicly available information

Francesco Nai

University of Zürich Winterthurerstrasse 190

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 August 2022 in ACS Medicinal Chemistry Letters
Verified
Journal Article
Open access
FNFrancesco Nai
Francesco Nai
RNRaed Nachawati
Raed Nachawati
FZFrantišek Zálešák
František Zálešák
XWXiang Wang
Xiang Wang
YLYaozong Li
Yaozong Li
ACAmedeo Caflisch
Amedeo Caflisch
We report 17 small-molecule ligands that compete with N6-methyladenosine (m6A) for binding to the m6A-reader domain of YTHDF2 (YT521-B homology domain family 2). We determined their binding mode at high resolution by X-ray crystallography and quantified their affinity by a fluorescence-based binding assay. 6-Cyclopropyluracil and a pyrazolopyrimidine derivative have favorable ligand efficiencies of 0.47 and 0.38 kcal mol-1 per non-hydrogen atom, respectively. They represent useful starting points for hit optimization.

12 December 2023 in ACS Bio & Med Chem Au
Verified
Journal Article
Open access
FNFrancesco Nai
Francesco Nai
MEMaria Paula Flores Espinoza
Maria Paula Flores Espinoza
AIAnnalisa Invernizzi
Annalisa Invernizzi
PVPablo Andrés Vargas-Rosales
Pablo Andrés Vargas-Rosales
OBOlga Bobileva
Olga Bobileva
ACAmedeo Caflisch
Amedeo Caflisch
We discovered the first inhibitors of the m7G-RNA writer METTL1 by high-throughput docking and an enzymatic assay based on luminescence. Eleven compounds, which belong to three different chemotypes, show inhibitory activity in the range 40-300 μM. Two adenine derivatives identified by docking have very favorable ligand efficiency of 0.34 and 0.31 kcal/mol per non-hydrogen atom, respectively. Molecular dynamics simulations provide evidence that the inhibitors compete with the binding of the cosubstrate S-adenosyl methionine to METTL1. We also present a soakable crystal form that was used to determine the structure of the complex of METTL1 with sinefungin at a resolution of 1.85 Å.

24 May 2024 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
FZFrantišek Zálešák
František Zálešák
FNFrancesco Nai
Francesco Nai
MHMarcin Herok
Marcin Herok
EBElena Bochenkova
Elena Bochenkova
RBRajiv K. Bedi
Rajiv K. Bedi
ACAmedeo Caflisch
Amedeo Caflisch
N6-Adenosine methylation (m6A) is a prevalent post-transcriptional modification of mRNA, with YTHDC1 being the reader protein responsible for recognizing this modification in the cell nucleus. Here, we present a protein structure-based medicinal chemistry campaign that resulted in the YTHDC1 inhibitor 40, which shows an equilibrium dissociation constant (Kd) of 49 nM. The crystal structure of the complex (1.6 Å resolution) validated the design. Compound 40 is selective against the cytoplasmic m6A-RNA readers YTHDF1-3 and YTHDC2 and shows antiproliferative activity against the acute myeloid leukemia (AML) cell lines THP-1, MOLM-13, and NOMO-1. For the series of compounds that culminated into ligand 40, the good correlation between the affinity in the biochemical assay and antiproliferative activity in the THP-1 cell line provides evidence of YTHDC1 target engagement in the cell. The binding to YTHDC1 in the cell is further supported by the cellular thermal shift assay. Thus, ligand 40 is a tool compound for studying the role of YTHDC1 in AML.

16 May 2022 in European Journal of Medicinal Chemistry Reports
Verified
Journal Article
Open access
YLYaozong Li
Yaozong Li
RBRajiv Kumar Bedi
Rajiv Kumar Bedi
FNFrancesco Nai
Francesco Nai
VRValentin von Roten
Valentin von Roten
ADAymeric Dolbois
Aymeric Dolbois
ACAmedeo Caflisch
Amedeo Caflisch

27 June 2025 in ACS Bio & Med Chem Au
Verified
Journal Article
Open access
AIAnnalisa Invernizzi
Annalisa Invernizzi
FNFrancesco Nai
Francesco Nai
RBRajiv Kumar Bedi
Rajiv Kumar Bedi
PVPablo Andrés Vargas-Rosales
Pablo Andrés Vargas-Rosales
YLYaozong Li
Yaozong Li
ACAmedeo Caflisch
Amedeo Caflisch
N 6-Adenosine methylation is the most abundant modification of mRNA. The three members of the YTH domain family proteins (YTHDF1–3) recognize in the cytoplasm the m6A-RNA modification. We screened a library of about 500,000 fragments (i.e., molecules with 11–20 non-hydrogen atoms) by docking into YTHDF2, which resulted in the identification of six active compounds among 47 tested in vitro (hit rate of 13%). The acquisition of 28 analogues of the docking hits provided an additional set of 10 active compounds (IC50 < 100 μM). Protein crystallography-guided optimization of a ligand-efficient fragment by the synthesis of 32 derivatives culminated in a series of YTHDF2 ligands, which show low-micromolar affinity measured by a fluorescence polarization (FP) assay and a homogeneous time-resolved fluorescence-based (HTRF) assay. The series is characterized by very favorable ligand efficiency (of about 0.3–0.4 kcal/mol per non-hydrogen atom). Compound 23 binds to YTHDF2 according to the FP and HTRF assays with a K d value of 1.3 μM and an IC50 value of 11 μM, respectively, and it is selective against all of the other YTH reader proteins. Several compounds of the series bind to the three YTHDF proteins with similar low-micromolar affinity, while they are less potent for YTHDC1 and YTHDC2. In contrast, compounds 17 and 30 bind also to YTHDC2, with K d of 6.3 and 4.9 μM, respectively. We also disclose six crystal structures of YTHDF2 in the complex with the fragments identified by docking.

18 June 2026 in Blood
Verified
Journal Article
Closed access
LRLili Ren
Lili Ren
HZHonghai Zhang
Honghai Zhang
OBOlga Bobileva
Olga Bobileva
FNFrancesco Nai
Francesco Nai
HBHongjie Bi
Hongjie Bi
RSRui Su
Rui Su
N7-methylguanosine (m7G), a prevalent modification in transfer RNAs (tRNAs), is primarily catalyzed by the methyltransferase METTL1. Although growing evidence supports a role for METTL1 in various tumors, its therapeutic potential and precise function in leukemia stem cell (LSC) homeostasis remain largely unexplored. Here, we identify METTL1 as a key regulator of LSC self-renewal and homing within bone marrow (BM) microenvironment through catalyzing m7G formation on a specific tRNA, tRNAPheGAA, thereby promoting leukemogenesis. Mechanistically, METTL1 loss significantly reduces m7G abundance and steady-state levels of tRNAPheGAA, leading to translation suppression and degradation of transcripts enriched with tRNAPheGAA-related codons, such as hematopoietic cell kinase (HCK). Decreased HCK expression disrupts CXCR4 signaling, impairing LSC self-renewal and BM homing. Therapeutically, we characterized a small-molecule METTL1 inhibitor (M1i; NSC137443), through high-throughput screening. Pharmacological inhibition of METTL1 demonstrated potent antitumor efficacy by reducing tRNA m7G levels and disrupting the tRNAPheGAA/HCK/CXCR4 cascade. Notably, targeting METTL1 significantly reduces LSC frequency, delays leukemogenesis, and prolongs survival in multiple acute myeloid leukemia models. Together, our findings establish a previously unrecognized role for METTL1 and its target tRNAPheGAA in LSC homeostasis and provide compelling proof-of-concept evidence that METTL1 is a druggable epitranscriptomic target for antileukemia therapy.